Engineering Cancer-Fighting Cells Inside the Body
Summary:
Companies are developing in vivo CAR-T therapies that edit immune cells directly in patients, potentially reducing costs from $500k to far less per treatment.
Trump’s New Executive Order Sparks Research Community Debate
Summary:
Trump’s executive order promotes scientific transparency but gives political appointees power to “correct” findings, worrying researchers about interference.
Rocket Pharmaceuticals Halts Trial After Patient Death in Gene Therapy Study
Summary:
FDA halted Rocket’s Danon disease gene therapy trial after patient died from capillary leak syndrome, raising safety questions about the treatment.
Lilly Diversifies Beyond Diabetes with $1 Billion SiteOne Pain Medicine Acquisition
Summary:
Eli Lilly acquired SiteOne Therapeutics for up to $1B, adding non-opioid pain treatments to diversify beyond its GLP-1 obesity and diabetes portfolio.
Is Science Getting Less Disruptive? The Great Innovation Debate Continues
Summary:
Researchers debate whether scientific breakthroughs are declining despite increased funding, with competing theories about measuring true innovation impact.
